These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 32725709)

  • 1. A crisis in US drug pricing: Consequences for patients with neuromuscular diseases, physicians, and society, part 2.
    Burns TM; Crowell JL; Smith AG
    Muscle Nerve; 2020 Nov; 62(5):573-578. PubMed ID: 32725709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A crisis in US drug pricing: Consequences for patients with neuromuscular diseases, physicians and society, part 1.
    Burns TM; Crowell JL; Smith AG
    Muscle Nerve; 2020 Nov; 62(5):567-572. PubMed ID: 32725634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rising Drug Costs for Neurologic Diseases.
    Crowell JL; Burns TM
    Continuum (Minneap Minn); 2020 Oct; 26(5):1392-1406. PubMed ID: 33003008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physician and Patient Adjustment to Reference Pricing for Drugs.
    Robinson JC; Whaley C; Brown TT; Dhruva SS
    JAMA Netw Open; 2020 Feb; 3(2):e1920544. PubMed ID: 32022881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Financial Impact of Alternative Pricing Benchmarks for Physician-Dispensed Drugs in the California Workers' Compensation System.
    Wilson L; Turkistani F; Tran DM; Huang W; Lin TK
    Appl Health Econ Health Policy; 2019 Apr; 17(2):231-242. PubMed ID: 30484140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of alternative pricing methods for drugs in California Workers' Compensation System: Fee-schedule pricing.
    Wilson L; Turkistani FA; Huang W; Tran DM; Lin TK
    PLoS One; 2018; 13(5):e0197449. PubMed ID: 29799850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is a new drug worth? An innovative model for performance-based pricing.
    Dranitsaris G; Dorward K; Owens RC; Schipper H
    Eur J Cancer Care (Engl); 2015 May; 24(3):313-20. PubMed ID: 25256668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fair global drug pricing.
    Campbell JD; Kaló Z
    Expert Rev Pharmacoecon Outcomes Res; 2018 Dec; 18(6):581-583. PubMed ID: 30215535
    [No Abstract]   [Full Text] [Related]  

  • 9. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Economics of Indication-Based Drug Pricing.
    Chandra A; Garthwaite C
    N Engl J Med; 2017 Jul; 377(2):103-106. PubMed ID: 28700848
    [No Abstract]   [Full Text] [Related]  

  • 11. Innovative Contracting for Pharmaceuticals and Medicaid's Best-Price Rule.
    Sachs R; Bagley N; Lakdawalla DN
    J Health Polit Policy Law; 2018 Feb; 43(1):5-18. PubMed ID: 28972020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. THE HIGH COST OF CURE: DOCTORS WADE INTO THE DRUG-PRICING BATTLES.
    Boerner H
    Physician Leadersh J; 2015; 2(5):46-8. PubMed ID: 26529877
    [No Abstract]   [Full Text] [Related]  

  • 13. Specialty pharmaceuticals: policy initiatives to improve assessment, pricing, prescription, and use.
    Robinson JC; Howell S
    Health Aff (Millwood); 2014 Oct; 33(10):1745-50. PubMed ID: 25288418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks.
    Gronde TV; Uyl-de Groot CA; Pieters T
    PLoS One; 2017; 12(8):e0182613. PubMed ID: 28813502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value-Based Pricing and State Reform of Prescription Drug Costs.
    Hwang TJ; Kesselheim AS; Sarpatwari A
    JAMA; 2017 Aug; 318(7):609-610. PubMed ID: 28692713
    [No Abstract]   [Full Text] [Related]  

  • 16. Value-Based Pricing and Patient Access for Specialty Drugs.
    Robinson JC; Howell S; Pearson SD
    JAMA; 2018 Jun; 319(21):2169-2170. PubMed ID: 29801023
    [No Abstract]   [Full Text] [Related]  

  • 17. How Medicare could get better prices on prescription drugs.
    Outterson K; Kesselheim AS
    Health Aff (Millwood); 2009; 28(5):w832-41. PubMed ID: 19643778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Payer and Policy Maker Steps to Support Value-Based Pricing for Drugs.
    Bach PB; Pearson SD
    JAMA; 2015 Dec; 314(23):2503-4. PubMed ID: 26619354
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmaceutical Reference Pricing: Does It Have a Future in the U.S.?
    Robinson JC
    Issue Brief (Commonw Fund); 2018 Sep; 2018():1-6. PubMed ID: 30199167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ICER Value Framework: Integrating Cost Effectiveness and Affordability in the Assessment of Health Care Value.
    Pearson SD
    Value Health; 2018 Mar; 21(3):258-265. PubMed ID: 29566831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.